SEC Form 4 · accession 0000911916-17-000032
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda C. Hogan
Officer — Head, Bus. Dev. and Strategy
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 3, 2017 | M | 718 | $6.75 | A | 718 | D | |
| Common StockF1 | Jan 3, 2017 | S | 718 | $36.25 | D | 0 | D | |
| Common Stock | Jan 4, 2017 | M | 185 | $7.56 | A | 185 | D | |
| Common StockF1 | Jan 4, 2017 | S | 185 | $36.40 | D | 0 | D | |
| Common Stock | Jan 5, 2017 | M | 1,677 | $10.00 | A | 1,677 | D | |
| Common StockF1,F2 | Jan 5, 2017 | S | 477 | $33.5548 | D | 1,200 | D | |
| Common StockF1 | Jan 5, 2017 | S | 600 | $34.40 | D | 600 | D | |
| Common StockF1,F3 | Jan 5, 2017 | S | 600 | $35.6083 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $6.75 | Jan 3, 2017 | M | 718 | D | — | Mar 4, 2026 | Common Stock | 718 | 26,594 | D |
| Stock Option (Right to Buy)F5 | $7.56 | Jan 4, 2017 | M | 185 | D | — | Aug 4, 2025 | Common Stock | 185 | 5,741 | D |
| Stock Option (Right to Buy)F6 | $10.00 | Jan 5, 2017 | M | 1,677 | D | — | May 5, 2025 | Common Stock | 1,677 | 46,966 | D |
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Ms. Hogan on March 24, 2016.
- F2Represents the sale of 477 shares in multiple transactions, ranging in price from $33.40 to $34.00 per share, resulting in a weighted average sale price of $33.5548. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Represents the sale of 600 shares in multiple transactions, ranging in price from $35.60 to $35.65 per share, resulting in a weighted average sale price of $35.6083. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F4Options vest in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month.
- F5Options vest as follows: one-third of the shares vested on August 4, 2016; and the remaining shares vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.
- F6Options vest as follows: 33% of the shares vested on May 5, 2016; and the remaining shares vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.